In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Sleep-disordered breathing is associated with ventricular arrhythmias in postmenopausal women with hypertension and coronary artery disease.

Session Poster Session 1

Speaker Valentina Tsareva

Congress : Heart Failure 2019

  • Topic : basic science
  • Sub-topic : Basic Science - Cardiac Diseases: Arrhythmias
  • Session type : Poster Session
  • FP Number : P632

Authors : V Tsareva (Smolensk,RU), N Novitskii (Kaluga,RU), K Sundukova (Smolensk,RU)

V Tsareva1 , N Novitskii2 , K Sundukova3 , 1Smolensk State Medical University, Therapy, ultrasound and functional diagnostics - Smolensk - Russian Federation , 2City Clinical Hospital 2 - Kaluga - Russian Federation , 3Smolensk State Medical University, Research center - Smolensk - Russian Federation ,


Background: Arterial hypertension (AH) and coronary artery disease (CAD) hold leading position in the structure of cardiovascular morbidity. High risk of developing AH and CAD becomes clinically significant after a woman enters menopause. The problem of sleep-disordered breathing is also being actively studied recently, as more and more information is accumulating about the negative effect of sleep apnea on the cardiovascular system. 
Purpose: To study the role of sleep-disordered breathing on ventricular arrhythmias (VA) in postmenopausal women with AH and CAD
Methods: 144 postmenopausal women with AH 1–2 degrees and chronic forms of CAD (mean age 66.6 ± 7.5 years) were examined. 27.1% of women had heart failure (NYHA I-II). The first group included 96 patients with VA. The second group consisted of 48 women without VA. The groups were divided into subgroups: A - index of apnea / hypopnea (AHI) <5 per hour of sleep; B - AHI = 5 per hour of sleep. Patients underwent holter monitoring of ECG and respiratory monitoring.To characterize the VA, the Lown and Wolf classification was used in the Ryan modification. VA 3 and higher gradations were taken to arrhythmias of high gradations.
Results: Patients with sleep-disordered breathing (AHI = 5 per hour of sleep) were found in the I (36.5%) and II (22.9%) groups, but in the group with VA of such patients there was a 13.6% increase (?² with the Yates correction = 1.9 p> 0.05). Patient didn’t significantly differ in the frequency of detection of VA I, III, IV? and V grades (?> 0.05). Frequent ventricular extrasystole (VE) by 22.2% (p <0.01 in the Fisher test) was more often recorded in patients in the IA subgroup (29.9% and 5.7% accordingly). Polymorphic pair VE more often (by 20.8%; p <0.01 by Fisher test) was detected in women of the IB subgroup. In patients with IB subgroups, arrhythmias of high gradations (51.4%) were more frequent (21.9% ?² = 4.56 p <0.05) compared with the IA subgroup.Using the method of calculating the odds ratio, it was found that the AHI = 5 episodes per hour of sleep increases the chance of development of high-grade VA by 2.5 times, polymorphic pair VE by 7 times.
Conclusions:Sleep-disordered breathing (AHI = 5 per hour of sleep) is associated with high-gradation VA and polymorphic paired VE.


index of apnea / hypopnea


95% CI

P criteria χ²

High gradations ventricular arrhythmias


1,16 - 5,92


Polymorphic pair ventricular extrasystole


1,75 - 28,22


OR - odds ratio; CI - confidence interval

Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from ESC Congress and ESC Asia with APSC & AFC
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s congress resources
  • 3Under 40 or in training - with a Combined Membership, access resources from all congresses
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are